<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-5633</journal-id>
<journal-title><![CDATA[Revista Colombiana de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Col. Cardiol.]]></abbrev-journal-title>
<issn>0120-5633</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Colombiana de Cardiologia. Oficina de Publicaciones]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-56332005000200003</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Cardiomiopatía amiloidea]]></article-title>
<article-title xml:lang="en"><![CDATA[Cardiac amyloidosis]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Marín]]></surname>
<given-names><![CDATA[Jorge E]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Duque]]></surname>
<given-names><![CDATA[Mauricio]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Medina]]></surname>
<given-names><![CDATA[Luis E]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Uribe]]></surname>
<given-names><![CDATA[William]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Velásquez]]></surname>
<given-names><![CDATA[Jorge E]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Clínica Medellín Servicio de electrofisiología, arritmias y marcapasos Cardiología]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2005</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2005</year>
</pub-date>
<volume>11</volume>
<numero>8</numero>
<fpage>389</fpage>
<lpage>396</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-56332005000200003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-56332005000200003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-56332005000200003&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[La amiloidosis es una enfermedad infiltrativa sistémica que compromete al corazón. Tiene orígenes genéticos y es una causa importante de cardiomiopatía restrictiva. Puede comprometer todas las estructuras cardiacas con predilección por el tejido miocárdico. Su manifestación más temprana y frecuente es la disfunción diastólica, aunque puede progresar a disfunción sistólica por infiltración miocárdica, dando lugar al síndrome de corazón rígido; además, compromete al sistema de conducción. Se debe sospechar en cualquier paciente con cardiomegalia no explicada por otra causa. Dentro de las herramientas diagnósticas se debe tener en cuenta la relación voltaje/ masa. La biopsia endomiocárdica es útil aunque no siempre positiva para la comprobación histológica. El tratamiento es de soporte y algunos casos se benefician del trasplante hepático.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Amyloidosis is an infiltrative systemic disease that may involve the heart. It has a genetic etiology and is an important cause of restrictive cardiomyopathy. It may involve all heart structures but has a great affinity for myocardial tissue. Diastolic dysfunction is the most early and frequent manifestation, although due to myocardial infiltration, it may progress to systolic dysfunction, resulting in a rigid heart syndrome. There is also an involvement of the conducting system. The condition may be suspected in any patient with cardiomegalia of unexplained cause. Among the diagnostic tools, the voltage/mass relation may be kept in mind. Endomyocardial biopsy is useful although it is not always positive through histological verification. The treatment consists of supportive measures and selected cases may benefit with hepatic transplantation.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[cardiomiopatía restrictiva]]></kwd>
<kwd lng="es"><![CDATA[amiloidosis cardiaca]]></kwd>
<kwd lng="es"><![CDATA[marcapasos]]></kwd>
<kwd lng="en"><![CDATA[restrictive cardiomyopathy]]></kwd>
<kwd lng="en"><![CDATA[cardiac amyloidosis]]></kwd>
<kwd lng="en"><![CDATA[pacemakers]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <P align="center"><font size="4" face="Times New Roman, Times, serif"><strong>Cardiomiopat&iacute;a    amiloidea</strong></font>     <div align="center"><I>       <P><strong><font face="Times New Roman, Times, serif">Cardiac amyloidosis</font></strong></P>   </I><font face="Times New Roman, Times, serif">        <P>Jorge E. Mar&iacute;n, MD.; Mauricio Duque, MD.; Luis E. Medina, MD., William      Uribe, MD.; Jorge E. Vel&aacute;squez, MD.    <BR>     Medell&iacute;n, Colombia</P>       <P>Servicio de electrofisiolog&iacute;a, arritmias y marcapasos. Cardiolog&iacute;a,      Cl&iacute;nica Medell&iacute;n, Medell&iacute;n. Colombia.    <BR>     Correspondencia: Mauricio Duque, MD. Cardiolog&iacute;a. Cl&iacute;nica Medell&iacute;n.      Calle 53 No. 46-38, segundo piso, Medell&iacute;n, Colombia.</P>   </font>       <P>   <HR WIDTH="63%">   <font face="Times New Roman, Times, serif">        <P ALIGN="JUSTIFY">La amiloidosis es una enfermedad infiltrativa sist&eacute;mica      que compromete al coraz&oacute;n. Tiene or&iacute;genes gen&eacute;ticos y      es una causa importante de cardiomiopat&iacute;a restrictiva. Puede comprometer      todas las estructuras cardiacas con predilecci&oacute;n por el tejido mioc&aacute;rdico.      Su manifestaci&oacute;n m&aacute;s temprana y frecuente es la disfunci&oacute;n      diast&oacute;lica, aunque puede progresar a disfunci&oacute;n sist&oacute;lica      por infiltraci&oacute;n mioc&aacute;rdica, dando lugar al s&iacute;ndrome      de coraz&oacute;n r&iacute;gido; adem&aacute;s, compromete al sistema de conducci&oacute;n.      Se debe sospechar en cualquier paciente con cardiomegalia no explicada por      otra causa. Dentro de las herramientas diagn&oacute;sticas se debe tener en      cuenta la relaci&oacute;n voltaje/ masa. La biopsia endomioc&aacute;rdica      es &uacute;til aunque no siempre positiva para la comprobaci&oacute;n histol&oacute;gica.      El tratamiento es de soporte y algunos casos se benefician del trasplante      hep&aacute;tico.</P>       <P ALIGN="JUSTIFY">Palabras clave: cardiomiopat&iacute;a restrictiva, amiloidosis      cardiaca, marcapasos.</P>   </font>       ]]></body>
<body><![CDATA[<P>   <HR WIDTH="63%">   <font face="Times New Roman, Times, serif"></P>        <P ALIGN="JUSTIFY">Amyloidosis is an infiltrative systemic disease that may      involve the heart. It has a genetic etiology and is an important cause of      restrictive cardiomyopathy. It may involve all heart structures but has a      great affinity for myocardial tissue. Diastolic dysfunction is the most early      and frequent manifestation, although due to myocardial infiltration, it may      progress to systolic dysfunction, resulting in a rigid heart syndrome. There      is also an involvement of the conducting system. The condition may be suspected      in any patient with cardiomegalia of unexplained cause. Among the diagnostic      tools, the voltage/mass relation may be kept in mind. Endomyocardial biopsy      is useful although it is not always positive through histological verification.      The treatment consists of supportive measures and selected cases may benefit      with hepatic transplantation.<B><EM> </P>       <P ALIGN="JUSTIFY">Key words: restrictive cardiomyopathy, cardiac amyloidosis,      pacemakers.</P>   </font>        <P>   <HR WIDTH="63%">   <font face="Times New Roman, Times, serif"><STRONG>        <P ALIGN="CENTER">Casos cl&iacute;nicos</P>   </STRONG>       <P ALIGN="JUSTIFY">Se recibieron dos pacientes, uno de g&eacute;nero masculino      y otro de g&eacute;nero femenino, con edades de 73 y 61 a&ntilde;os, quienes      consultaron por s&iacute;ntomas de astenia, adinamia y fatigabilidad y presentaron      episodios de fibrilaci&oacute;n auricular parox&iacute;stica. En uno de ellos      se document&oacute; disfunci&oacute;n sinusal avanzada y en el otro bloqueo      aur&iacute;culo-ventricular intermitente. En ambos, el electrocardiograma      demostr&oacute; bajo voltaje generalizado.</P>       <P ALIGN="JUSTIFY">En el ecocardiograma se evidenci&oacute; hipertrofia ventricular      izquierda con signos de refringencia que sugirieron enfermedad infiltrativa;      en ambos la fracci&oacute;n de expulsi&oacute;n fue normal y se demostr&oacute;      disfunci&oacute;n diast&oacute;lica. Se realiz&oacute; tomograf&iacute;a axial      computarizada (TAC) multidetector de t&oacute;rax, la cual mostr&oacute; &aacute;reas      de menor densidad en el coraz&oacute;n que son compatibles con dep&oacute;sitos      de amiloide (<A HREF="#figura1">Figura 1</A>). La TAC de abdomen no evidenci&oacute;      infiltraci&oacute;n en v&iacute;sceras extracardiacas. Uno de los pacientes      ten&iacute;a biopsias de grasa periumbilical y de recto, negativas para dep&oacute;sito      de amiloide. Se descartaron causas secundarias de amiloidosis. A ambos se      les implantaron marcapasos bicamerales; durante este procedimiento se demostr&oacute;      una onda P y R de muy bajo voltaje, con umbrales normales. Los dos pacientes      desarrollaron incremento importante de los umbrales, por lo que se llevaron      a reposici&oacute;n de electrodos auriculares. El diagn&oacute;stico de amiloidosis      cardiaca se realiz&oacute; por biopsia endomioc&aacute;rdica en ambos pacientes.</P>   </font>       <P ALIGN="CENTER">&nbsp;</P>       <P ALIGN="CENTER"><font face="Times New Roman, Times, serif"><A NAME="figura1"></A></font></P>       <P ALIGN="CENTER"><font face="Times New Roman, Times, serif"><IMG SRC="/img/revistas/rcca/v11n8/a3f1.gif" WIDTH=350 HEIGHT=370></font></P>       ]]></body>
<body><![CDATA[<P ALIGN="CENTER">&nbsp;</P>       <P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">Uno de los pacientes      muri&oacute; un a&ntilde;o despu&eacute;s del diagn&oacute;stico de amiloidosis      cardiaca por falla cardiaca, refractaria al tratamiento m&eacute;dico convencional.      El otro paciente se llev&oacute; a transplante hep&aacute;tico con evoluci&oacute;n      satisfactoria y a la fecha se reporta buena evoluci&oacute;n.</font></P>   <STRONG>       <P ALIGN="CENTER"><font face="Times New Roman, Times, serif">Introducci&oacute;n</font></P>   </STRONG>       <P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">El t&eacute;rmino      amiloidosis hace referencia al dep&oacute;sito tisular extracelular de fibras      compuestas de varias subunidades de bajo peso molecular (5 a 25 kD) de una      variedad de prote&iacute;nas s&eacute;ricas. El dep&oacute;sito amiloideo      puede ocurrir en una variedad de &oacute;rganos entre los que se incluyen      coraz&oacute;n, ri&ntilde;&oacute;n e h&iacute;gado, que son responsables      a menudo de la morbimortalidad de la enfermedad.</font></P>       <P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">Las dos formas      m&aacute;s comunes de amiloidosis son: amiloidosis primaria (AL), en la que      la prote&iacute;na amiloidea est&aacute; compuesta por fragmentos monoclonales      de cadenas livianas, lo cual es una discrasia de c&eacute;lulas plasm&aacute;ticas;      y amiloidosis secundaria (AA), que se caracteriza por fragmentos de prote&iacute;na      amiloidea A, la cual se asocia con des&oacute;rdenes inflamatorios cr&oacute;nicos.    <BR>     Entre las causas gen&eacute;ticas de amiloidosis, las mutaciones en el gen      para la transtiretina (tambi&eacute;n llamada prealb&uacute;mina), son las      que m&aacute;s se asocian con enfermedad cardiaca; con algunas mutaciones      los dep&oacute;sitos amiloideos se limitan cl&iacute;nicamente al miocardio.</font></P>   <STRONG>       <P ALIGN="CENTER"><font face="Times New Roman, Times, serif">Importancia del      tipo de amiloidosis</font></P>   </STRONG>       <P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">Patol&oacute;gicamente      la cardiomiopat&iacute;a amiloidea se define por la deposici&oacute;n amiloidea      en el miocardio (<A HREF="#figura2">Figura 2</A>) y cl&iacute;nicamente por      signos de disfunci&oacute;n mioc&aacute;rdica o del sistema de conducci&oacute;n.      La evidencia cl&iacute;nica de compromiso cardiaco ocurre hasta en 50% de      los pacientes con AL, en 10% con AA y en menos del 5% con s&iacute;ndromes      familiares (1, 2).</font></P>       <P ALIGN="CENTER">&nbsp;</P>       <P ALIGN="CENTER"><font face="Times New Roman, Times, serif"><A NAME="figura2"></A></font></P>       ]]></body>
<body><![CDATA[<P ALIGN="CENTER"><font face="Times New Roman, Times, serif"><IMG SRC="/img/revistas/rcca/v11n8/a3f2.gif" WIDTH=350 HEIGHT=329></font></P>       <P ALIGN="CENTER">&nbsp;</P>   <STRONG>       <P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">Amiloidosis primaria      comparada con otros tipos de amiloidosis</font></P>   </STRONG>       <P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">El compromiso      cardiaco en amiloidosis primaria a menudo lleva a disfunci&oacute;n cardiaca      significativa, mientras que la amiloidosis secundaria y las formas familiares,      tiene un compromiso m&aacute;s leve (1-4). Esta distinci&oacute;n se ilustra      en una revisi&oacute;n de 36 pacientes con cardiomiopat&iacute;a amiloidea:      12 con forma familiar y 24 con amiloidosis secundaria (3). Aunque los dos      grupos tienen similares hallazgos ecocardiogr&aacute;ficos, las tasas de supervivencia      a un a&ntilde;o son de 92% y 38% respectivamente, y todas las muertes son      de origen cardiaco (<A HREF="#figura3">Figura 3</A>).</font></P>       <P ALIGN="CENTER">&nbsp;</P>       <P ALIGN="CENTER"><font face="Times New Roman, Times, serif"><A NAME="figura3"></A></font></P>       <P ALIGN="CENTER"><font face="Times New Roman, Times, serif"><IMG SRC="/img/revistas/rcca/v11n8/a3f3.gif" WIDTH=399 HEIGHT=302></font></P>       <P ALIGN="JUSTIFY">&nbsp;</P>       <P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">La diferencia      en el pron&oacute;stico refleja el grado variable de la infiltraci&oacute;n      amiloidea del miocardio. Habitualmente, se observan dep&oacute;sitos difusos      extensos en pacientes con AA, mientras que los focos aislados esparcidos son      m&aacute;s caracter&iacute;sticos de otros tipos de amiloidosis. Otro posible      factor que contribuye a la diferencia en el pron&oacute;stico, es que las      caracter&iacute;sticas bioqu&iacute;micas de los distintos tipos de fibrillas      amiloideas tienen variados efectos patol&oacute;gicos en el miocardio (3).</font></P>   <STRONG>       <P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">Mutaciones de      la transtiretina</font></P>   </STRONG>       ]]></body>
<body><![CDATA[<P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">Hay una variabilidad      en la severidad relativa de la enfermedad cardiaca y extracardiaca entre los      pacientes con diferentes mutaciones del gen encargado de codificar la transtiretina      (TTR), en la que hay mayor compromiso en la poblaci&oacute;n negra debido,      en parte, a la presencia de un alelo de la TTR amiloidog&eacute;nico heterocigoto,      en el cual la isoleucina se sustituye por valina en la posici&oacute;n 122      (Ile 122). Este alelo no est&aacute; presente en ning&uacute;n paciente de      raza blanca con amiloidosis cardiaca (5).</font></P>       <P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">Reportes iniciales      suger&iacute;an que la amiloidosis cardiaca senil, raras veces era una causa      de morbimortalidad significativa (6, 7); sin embargo, &eacute;sta puede asociarse      con fibrilaci&oacute;n auricular, da&ntilde;o en el sistema de conducci&oacute;n      y falla cardiaca (5).</font></P>   <STRONG>       <P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">Correlaciones      clinicopatol&oacute;gicas</font></P>   </STRONG>       <P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">Los estudios con      necropsia de amiloidosis cardiaca, muestran un miocardio engrosado con crecimiento      ventricular y auricular. La inspecci&oacute;n macrosc&oacute;pica revela una      consistencia cauchosa y la presencia de trombos intracardiacos (8).</font></P>       <P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">El examen microsc&oacute;pico      del miocardio muestra dep&oacute;sitos hialinos que predominan en el espacio      extracelular. Las fibrillas ligan la coloraci&oacute;n de rojo congo (llevando      a una birrefringencia verde bajo luz polarizada) (<A HREF="#figura4">Figura      4</A>).</font></P>       <P ALIGN="CENTER">&nbsp;</P>       <P ALIGN="CENTER"><font face="Times New Roman, Times, serif"><A NAME="figura4"></A></font></P>       <P ALIGN="CENTER"><font face="Times New Roman, Times, serif"><img src="/img/revistas/rcca/v11n8/a3f4.gif" width="350" height="334"></font></P>       <P ALIGN="CENTER">&nbsp;</P>       <P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">Desde el punto      de vista cl&iacute;nico, el compromiso del miocardio ventricular y del sistema      de conducci&oacute;n es lo m&aacute;s importante. No obstante, pueden encontrarse      dep&oacute;sitos amiloideos cl&iacute;nicamente significativos en las siguientes      localizaciones (9):</font></P>       ]]></body>
<body><![CDATA[<P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">- Arterias coronarias      intramioc&aacute;rdicas y epic&aacute;rdicas.    <BR>     - Miocardio auricular.    <BR>     - V&aacute;lvulas cardiacas.    <BR>     - Pericardio.</font></P>       <P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">La acumulaci&oacute;n      de tejido amiloideo en una o m&aacute;s de estas &aacute;reas, puede llevar      a distintas presentaciones cl&iacute;nicas.</font></P>   <STRONG>       <P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">Disfunci&oacute;n      mioc&aacute;rdica</font></P>   </STRONG>       <P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">Los dep&oacute;sitos      amiloideos difusos pueden llevar a da&ntilde;o en la funci&oacute;n mioc&aacute;rdica      por tres formas diferentes:</font></P>       <P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">- Reemplazo del      tejido mioc&aacute;rdico funcional con prote&iacute;na amiloidea, lo cual      lleva a reducci&oacute;n en la funci&oacute;n sist&oacute;lica (10).    <BR>     - Infiltraci&oacute;n difusa del miocardio ventricular izquierdo con fibrillas      inertes y r&iacute;gidas, que lleva a da&ntilde;o en la relajaci&oacute;n      y disfunci&oacute;n diast&oacute;lica (10, 11). En los pacientes que a&uacute;n      preservan la funci&oacute;n sist&oacute;lica, esta anormalidad puede ser dif&iacute;cil      de distinguir de la pericarditis constrictiva.</font></P>       <P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">En algunos casos      de marcada infiltraci&oacute;n amiloidea, la combinaci&oacute;n de un patr&oacute;n      de llenado restrictivo severo y una contracci&oacute;n ventricular izquierda      reducida, pueden causar el llamado &amp;laquo;s&iacute;ndrome de coraz&oacute;n      r&iacute;gido&amp;raquo; (12). Este cuadro cl&iacute;nico es probablemente      &uacute;nico para la amiloidosis.</font></P>       ]]></body>
<body><![CDATA[<P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">Desde el punto      de vista patol&oacute;gico, las caracter&iacute;sticas bioqu&iacute;micas      de las cadenas livianas pueden ser importantes. En un modelo experimental      en el que se usaron corazones murinos aislados, la infusi&oacute;n de cadenas      livianas de pacientes con AL que ten&iacute;a compromiso cardiaco severo,      deterior&oacute; de manera marcada la relajaci&oacute;n ventricular sin afectar      la funci&oacute;n sist&oacute;lica (11). Este hallazgo es similar al que se      observa en pacientes con mieloma m&uacute;ltiple, en el cual las caracter&iacute;sticas      bioqu&iacute;micas de las cadenas livianas determinan el tipo de enfermedad      renal y extrarrenal.</font></P>   <STRONG>       <P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">Anormalidades      electrofisiol&oacute;gicas</font></P>   </STRONG>       <P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">En la enfermedad      cardiaca amiloidea es com&uacute;n aceptar el sistema de conducci&oacute;n.      Las anomal&iacute;as no son a menudo cl&iacute;nicamente significativas, pero      pueden ocurrir disturbios en la conducci&oacute;n y arritmias serias, incluso      muerte s&uacute;bita (5, 13, 14), as&iacute; como fibrilaci&oacute;n auricular,      com&uacute;n en casos avanzados.</font></P>       <P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">Aunque el nodo      sinusal puede involucrarse en forma patol&oacute;gica (15), la funci&oacute;n      anormal parece ser m&aacute;s com&uacute;n en el sistema His-Purkinje. Esto      se ilustr&oacute; en un estudio electrofisiol&oacute;gico de 25 pacientes      con AL y compromiso cardiaco (13). La funci&oacute;n sinusal y nodal auriculoventricular      se preserv&oacute; en muchos pacientes, pero los tiempos de conducci&oacute;n      infra hisianos estuvieron usualmente prolongados, de tal forma que 13 pacientes      tuvieron intervalos HV mayores de 55 mseg y 12 pacientes mostraron intervalos      HV mayores de 80 mseg. La prolongaci&oacute;n del intervalo HV puede no sospecharse      cl&iacute;nicamente si el QRS es estrecho en el electrocardiograma (EKG) de      superficie (<A HREF="#figura5">Figura 5</A>).</font></P>       <P ALIGN="CENTER">&nbsp;</P>       <P ALIGN="CENTER"><font face="Times New Roman, Times, serif"><A NAME="figura5"></A></font></P>       <P ALIGN="CENTER"><font face="Times New Roman, Times, serif"><IMG SRC="/img/revistas/rcca/v11n8/a3f5.gif" WIDTH=450 HEIGHT=303></font></P>       <P ALIGN="CENTER">&nbsp;</P>       <P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">El compromiso      del sistema Purkinje y del miocardio ventricular, puede llevar a activaci&oacute;n      mioc&aacute;rdica retardada, la cual puede detectarse en el EKG de actividad      promediada (14). En un reporte de 133 pacientes con AL, los potenciales tard&iacute;os      en el EKG de se&ntilde;al promediada fueron significativamente m&aacute;s      frecuentes en pacientes con evidencia ecocardiogr&aacute;fica de compromiso      amiloideo cardiaco (31% vs. 9% en aquellos con EKG normal). Tanto la prolongaci&oacute;n      del intervalo HV como los potenciales tard&iacute;os, se asocian independientemente      con un alto riesgo de muerte s&uacute;bita cardiaca (13, 14). </font></P>   <STRONG>       <P ALIGN="CENTER"><font face="Times New Roman, Times, serif">Manifestaciones      cl&iacute;nicas</font></P>   </STRONG>       ]]></body>
<body><![CDATA[<P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">La presentaci&oacute;n      cl&iacute;nica de la enfermedad es usualmente dominada por falla cardiaca      del lado derecho. Estas manifestaciones incluyen edema perif&eacute;rico,      elevaci&oacute;n de la presi&oacute;n venosa yugular, hipotensi&oacute;n ortost&aacute;tica      (como resultado del inadecuado llenado ventricular y presencia de neuropat&iacute;a      auton&oacute;mica). Hay tambi&eacute;n presencia de bajo gasto cardiaco con      disfunci&oacute;n renal, da&ntilde;o en la perfusi&oacute;n org&aacute;nica,      fatiga y edema pulmonar. El examen f&iacute;sico puede revelar soplo sist&oacute;lico      (debido a la regurgitaci&oacute;n mitral y tric&uacute;spide) y baja presi&oacute;n      de pulso (debido al bajo volumen latido).</font></P>       <P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">El s&iacute;ncope      es un s&iacute;ntoma com&uacute;n, multifactorial, dentro del que cabe destacar      bradiarritmias y/o taquiarritmias e hipotensi&oacute;n postural (16). </font></P>       <P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">El compromiso      sintom&aacute;tico del sistema de conducci&oacute;n que requiere un marcapaso      permanente es poco com&uacute;n (17). </font></P>       <P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">Los pacientes      con dep&oacute;sito amiloideo extenso en las arterias coronarias pueden desarrollar      s&iacute;ntomas de angina t&iacute;pica (18-21). Los vasos involucrados son      t&iacute;picamente peque&ntilde;os e intramioc&aacute;rdicos, no epic&aacute;rdicos;      como resultado, la angiograf&iacute;a coronaria en estos pacientes es normal.      </font></P>       <P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">Raras veces, la      acumulaci&oacute;n amiloidea en el septo puede simular cardiomiopat&iacute;a      hipertr&oacute;fica (22), mientras que los dep&oacute;sitos en el pericardio      pueden producir taponamiento cardiaco (23, 24).</font></P>   <STRONG>       <P ALIGN="CENTER"><font face="Times New Roman, Times, serif">Diagn&oacute;stico</font></P>   </STRONG>       <P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">La presencia de      amiloidosis debe descartarse en cualquier paciente con cardiomegalia no explicada,      falla cardiaca, proteinuria severa o hepatomegalia. Hallazgos como anemia,      dolor &oacute;seo o hipercalcemia sugieren AL con mieloma m&uacute;ltiple;      mientras una historia de enfermedad inflamatoria cr&oacute;nica, como artritis      reumatoidea, sugiere AA. </font></P>       <P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">El diagn&oacute;stico      de amiloidosis se confirma por la observaci&oacute;n de dep&oacute;sitos amiloideos      tisulares en pan&iacute;culo adiposo abdominal, recto o ri&ntilde;&oacute;n.      Los dep&oacute;sitos amiloideos en el coraz&oacute;n pueden llevar a anomal&iacute;as      detectables con varios ex&aacute;menes.</font></P>   <font face="Times New Roman, Times, serif">       <P ALIGN="JUSTIFY"><strong>Electrocardiograf&iacute;a</strong> </P>       <P ALIGN="JUSTIFY">El hallazgo m&aacute;s com&uacute;n en amiloidosis cardiaca      es el bajo voltaje en las derivaciones de las extremidades y precordiales;      &eacute;ste ocurre en aproximadamente 50% de los pacientes, particularmente      en aquellos con AL (1, 3, 25). Otros cambios que pueden ocurrir incluyen anomal&iacute;as      de la conducci&oacute;n (bloqueo auriculoventricular de II y III grado), fibrilaci&oacute;n      auricular y patrones de seudoinfarto. Todas estas anomal&iacute;as son no      espec&iacute;ficas.</P>   <STRONG>       ]]></body>
<body><![CDATA[<P ALIGN="JUSTIFY">Ecocardiograf&iacute;a</P>   </STRONG>       <P ALIGN="JUSTIFY">La disfunci&oacute;n diast&oacute;lica es el hallazgo mas      com&uacute;n, m&aacute;s temprano y m&aacute;s importante en amiloidosis cardiaca.      &Eacute;sta es evidente antes de la disfunci&oacute;n sist&oacute;lica en      aquellos pacientes que llegan a tener falla de bomba. Tambi&eacute;n se puede      evidenciar disfunci&oacute;n diast&oacute;lica ventricular derecha (26). En      casos de enfermedad avanzada, la amiloidosis cardiaca es una causa de cardiomiopat&iacute;a      restrictiva que simula pericarditis constrictiva. La evaluaci&oacute;n Doppler      de las velocidades de flujo sangu&iacute;neo transmitral y transtric&uacute;spide,      muestra un patr&oacute;n de llenado restrictivo con fuerte dominancia de la      onda E y corto tiempo de desaceleraci&oacute;n.</P>       <P ALIGN="JUSTIFY">En pacientes con amiloidosis manifiesta, la ecocardiograf&iacute;a      frecuentemente muestra engrosamiento sim&eacute;trico de las paredes ventriculares      izquierdas (27), aunque hay casos de compromiso septal asim&eacute;trico que      produce una apariencia similar a la cardiomiopat&iacute;a hipertr&oacute;fica      obstructiva (22). Tambi&eacute;n se pueden observar c&aacute;maras ventriculares      peque&ntilde;as, engrosamiento del septo auricular y dilataci&oacute;n auricular      (28). </P>       <P ALIGN="JUSTIFY">El hallazgo ecocardiogr&aacute;fico m&aacute;s distintivo      en amiloidosis cardiaca, es la apariencia granular del miocardio, la cual      es el resultado de la presencia de n&oacute;dulos de col&aacute;geno y amiloide      en el coraz&oacute;n (25, 27, 29). No obstante, cuando &eacute;ste se halla      solo, es relativamente no espec&iacute;fico ya que otras enfermedades infiltrativas      tambi&eacute;n lo pueden generar. </P>       <P ALIGN="JUSTIFY">La ecocardiograf&iacute;a tambi&eacute;n provee informaci&oacute;n      pron&oacute;stica, como se demostr&oacute; en una serie hecha por Dubrey y      colaboradores(14) en la cual en 133 pacientes con AL la presencia de muerte      cardiaca fue m&aacute;s com&uacute;n en 77 pacientes con ecocardiograma anormal      que mostraba evidencia de dep&oacute;sito amiloideo, en comparaci&oacute;n      con aquellos que ten&iacute;an ecocardiograma normal (<A HREF="#figura6">Figura      7</A>)</P>       <P ALIGN="JUSTIFY">.</P>       <P ALIGN="CENTER"><A NAME="figura6"></A></P>       <P ALIGN="CENTER"><IMG SRC="/img/revistas/rcca/v11n8/a3f6.gif" WIDTH=480 HEIGHT=330></P>   </font>       <P ALIGN="CENTER">&nbsp;</P>       <P ALIGN="CENTER"><font face="Times New Roman, Times, serif"><A NAME="figura7"></A></font></P>       ]]></body>
<body><![CDATA[<P ALIGN="CENTER"><font face="Times New Roman, Times, serif"><IMG SRC="/img/revistas/rcca/v11n8/a3f7.gif" WIDTH=350 HEIGHT=480></font></P>       <P ALIGN="CENTER">&nbsp;</P>   <STRONG>       <P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">Relaci&oacute;n      voltaje-masa</font></P>   </STRONG>       <P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">Las limitaciones      de los ex&aacute;menes antes mencionados para el diagn&oacute;stico de amiloidosis      cardiaca, llevaron a la evaluaci&oacute;n de otras modalidades, una de las      cuales es la relaci&oacute;n voltaje-masa cardiaca. La combinaci&oacute;n      de una masa ventricular incrementada (medida ecocardiogr&aacute;ficamente)      con reducci&oacute;n en el voltaje electrocardiogr&aacute;fico, es &uacute;nica      para esta cardiomiopat&iacute;a infiltrativa (25, 30, 31). Otras enfermedades      que se caracterizan por bajo voltaje en el EKG (taponamiento, derrame peric&aacute;rdico,      enfisema) no se asocian con incremento en la masa cardiaca, mientras que enfermedades      con masa cardiaca incrementada (hipertensi&oacute;n, hipertrofia) usualmente      no se asocian con bajo voltaje en el EKG (<A HREF="#figura9">Figura 9</A>).      </font></P>       <P ALIGN="CENTER">&nbsp;</P>       <P ALIGN="CENTER"><font face="Times New Roman, Times, serif"><A NAME="figura8"></A></font></P>       <P ALIGN="CENTER"><font face="Times New Roman, Times, serif"><IMG SRC="/img/revistas/rcca/v11n8/a3f8.gif" WIDTH=391 HEIGHT=320></font></P>       <P ALIGN="CENTER">&nbsp;</P>       <P ALIGN="CENTER"><font face="Times New Roman, Times, serif"><A NAME="figura9"></A></font></P>       <P ALIGN="CENTER"><font face="Times New Roman, Times, serif"><img src="/img/revistas/rcca/v11n8/a3f9.gif" width=400 height=320></font></P>       ]]></body>
<body><![CDATA[<P ALIGN="CENTER">&nbsp;</P>   <font face="Times New Roman, Times, serif">       <P ALIGN="JUSTIFY"><strong>Biopsia endomioc&aacute;rdica</strong></P>   </font> </div> <font face="Times New Roman, Times, serif">     <P ALIGN="JUSTIFY">Este examen permite observar dep&oacute;sitos amiloideos en    los pacientes con amiloidosis sist&eacute;mica documentada y sospecha de compromiso    cardiaco. En dos estudios retrospectivos la biopsia mioc&aacute;rdica fue positiva    en 40 de 41 pacientes, lo cual sugiere que este procedimiento es altamente sensible    en pacientes seleccionados de manera adecuada (32, 33). </P>     <P ALIGN="JUSTIFY">Las indicaciones para la realizaci&oacute;n de biopsia mioc&aacute;rdica    por posible amiloidosis cardiaca, no est&aacute;n a&uacute;n bien definidas;    sin embargo, este procedimiento puede ser &uacute;til cuando hay un paciente    con cardiomiopat&iacute;a restrictiva la cual no puede ser diferenciada por    otros m&eacute;todos de pericarditis constrictiva. Adem&aacute;s, se debe contemplar    su realizaci&oacute;n cuando los hallazgos positivos alterar&aacute;n la toma    de decisiones en el manejo cl&iacute;nico.</P> <STRONG>      <P ALIGN="CENTER">Tratamiento</P> </STRONG>      <P ALIGN="JUSTIFY">El tratamiento de la amiloidosis cardiaca sintom&aacute;tica    es usualmente inefectivo y por lo general consiste en medidas de soporte.</P> <STRONG>      <P ALIGN="JUSTIFY">Amiloidosis primaria</P> </STRONG>      <P ALIGN="JUSTIFY">En estos pacientes se reporta un promedio en la supervivencia    entre 6 y 9 meses cuando desarrollan falla cardiaca (34, 35) y de 1,1 a&ntilde;os    en aquellos con cualquier signo de compromiso cardiaco. La presencia de dilataci&oacute;n    desproporcionada del ventr&iacute;culo derecho puede asociarse con un pobre    pron&oacute;stico (supervivencia en promedio de 4 meses) (28).</P>     <P ALIGN="JUSTIFY">&aacute;rea ventricular fin di&aacute;stole izquierda    <BR>   &aacute;rea ventricular fin di&aacute;stole derecha </P>     ]]></body>
<body><![CDATA[<P ALIGN="JUSTIFY">Dilataci&oacute;n VD desproporcionada.</P>     <P ALIGN="JUSTIFY">Varios reportes que usaron quimioterapia (melfal&aacute;n-prednisona)    mostraron resultados favorables en algunos pacientes (36-38). </P>     <P ALIGN="JUSTIFY">Trasplante hep&aacute;tico o cardiaco</P>     <P ALIGN="JUSTIFY">El transplante cardiaco no se ha utilizado como rutina en pacientes    con AA o AL debido a que frecuentemente &eacute;stos tienen dep&oacute;sito    amiloideo extracardiaco en forma severa, a que pueden progresar a mieloma m&uacute;ltiple    y por la posibilidad de recurrencia en el coraz&oacute;n trasplantado. Pese    a ello, hay reportes anecd&oacute;ticos que sugieren beneficio temporal del    trasplante cardiaco (39-41) (<A HREF="#figura10">Figura 10</A>).</P> </font>      <P ALIGN="CENTER">&nbsp;</P>     <P ALIGN="CENTER"><font face="Times New Roman, Times, serif"><A NAME="figura10"></A></font></P>     <P ALIGN="CENTER"><font face="Times New Roman, Times, serif"><IMG SRC="/img/revistas/rcca/v11n8/a3f10.gif" WIDTH=400 HEIGHT=324></font></P>     <P ALIGN="JUSTIFY">&nbsp;</P>     <P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">El trasplante hep&aacute;tico    puede ser curativo en casos de amiloidosis familiar debido a un defecto en la    TTR. </font></P> <STRONG>     <P ALIGN="CENTER"><font face="Times New Roman, Times, serif">Conclusi&oacute;n</font></P> </STRONG>     ]]></body>
<body><![CDATA[<P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">El compromiso cardiaco    de la amiloidosis debe sospecharse en todos los pacientes con cardiomiopat&iacute;a    restrictiva. &Eacute;stos desarrollan disfunci&oacute;n diast&oacute;lica temprana    y anomal&iacute;as no espec&iacute;ficas en el sistema de conducci&oacute;n.</font></P>     <P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">Los hallazgos ecocardiogr&aacute;ficos    y electrocardiogr&aacute;ficos son altamente sugestivos. El papel de la biopsia    endomioc&aacute;rdica a&uacute;n no se define por completo. Las modalidades    terap&eacute;uticas disponibles son s&oacute;lo medidas de soporte.</font></P> <STRONG>     <P ALIGN="CENTER"><font face="Times New Roman, Times, serif">Bibliograf&iacute;a</font></P> </STRONG>     <!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">1. Gertz MA, Kyle    RA. Primary systemic amyloidosis. A diagnostic primer. Mayo Clin Proc 1989;    64:1505.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000126&pid=S0120-5633200500020000300001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">2. Kyle RA. Amyloidosis.    Circulation 1995; 91:1269.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000127&pid=S0120-5633200500020000300002&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">3. Dubrey SW, Skinner    M, LaValley M, et al. Familial and primary (AL) cardiac amyloidosis: echocardiographically    similar diseases with distinctly 5 different clinical outcomes. Heart 1997;    78: 74.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000128&pid=S0120-5633200500020000300003&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">4. Gertz A, Kyle    RA, Thibodeau SN. Familial amyloidosis: A study of 52 North American-born patients    examined during a 30 year period. Mayo Clin Proc 1992; 67:428.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000129&pid=S0120-5633200500020000300004&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">5. Jacobson DR,    Pastore RD, Yaghoubian R, et al. Variant sequence transthyretin (isoleucine    122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 1997;    336: 466.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000130&pid=S0120-5633200500020000300005&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">6. Cornwell GG,    Murdoch BS, Kyle RA, et al. Frequency and distribution of senile cardiovascular    amyloid. Am J Med 1983; 75: 618.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000131&pid=S0120-5633200500020000300006&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">7. Olson LJ, Gertz    MA, Edwards WD, et al. Senile cardiac amyloidosis with myocardial dysfunction.    Diagnosis by endomyocardial biopsy and immunohistochemistry. N Engl J Med 1987;    317: 738.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000132&pid=S0120-5633200500020000300007&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">8. Roberts WC, Waller    BF. Cardiac amyloidosis causing cardiac dysfunction: analysis of 54 necropsy    patients. Am J Cardiol 1983; 52: 137.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000133&pid=S0120-5633200500020000300008&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">9. Smith TJ, Kyle    RA. Clinical significance of histological patterns of cardiac amyloidosis. Mayo    Clin Proc 1984; 59: 547.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000134&pid=S0120-5633200500020000300009&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">10. Swanton RH,    Brooksby IAB, Davies MJ, et al. Systolic and diastolic ventricular function    in cardiac amyloidosis. Am J Cardiol 1977; 39: 658.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000135&pid=S0120-5633200500020000300010&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">11. Liao R, Jain    M, Teller P, et al. Infusion of light chains from patients with cardiac amyloidosis    causes diastolic dysfunction in isolated mouse hearts. Circulation 2001; 104:    1594.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000136&pid=S0120-5633200500020000300011&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">12. Chew C, Ziady    GM, Raphael MJ, Oakley CM. The functional defect in amyloid heart disease. The    «stiff heart» syndrome. Am J Cardiol 1975; 36:43 (abstract).</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000137&pid=S0120-5633200500020000300012&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">13. Reisinger J,    Dubrey SW, Lavalley M, et al. Electrophysiologic abnormalities in AL (primary)    amyloidosis with cardiac involvement. J Am Coll Cardiol 1997; 30:1046.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000138&pid=S0120-5633200500020000300013&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">14. Dubrey SW, Bilazarian    S, LaValley M, et al. Signal averaged electrocardiography in patients with AL    (primary) amyloidosis. Am Heart J 1997; 134: 994.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000139&pid=S0120-5633200500020000300014&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">15. Ridolfi RL,    Bulkley BH, Hutchins GM. The conduction system in cardiac amyloidosis. Am J    Med 1977; 62: 677.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000140&pid=S0120-5633200500020000300015&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">16. Chamarthi B,    Dubrey SW, Cha K, et al. Features and prognosis of exertional syncope in light-chain    associated AL cardiac amyloidosis. Am J Cardiol 1997; 80: 1242.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000141&pid=S0120-5633200500020000300016&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">17. Mathew V, Olson    LJ, Gertz MA, et al. Symptomatic conduction system disease in cardiac amyloidosis.    Am J Cardiol 1997; 80: 1491.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000142&pid=S0120-5633200500020000300017&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">18. Al Suwaidi J,    Velianou JL, Gertz MA, et al. Systemic amyloidosis presenting as angina pectoris.    Ann Intern Med 1999; 131: 838.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000143&pid=S0120-5633200500020000300018&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">19. Mueller PS,    Edwards WD, Gertz MA. Symptomatic ischemic heart disease resulting from obstructive    intramural coronary amyloidosis. Am J Med 2000; 109: 181.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000144&pid=S0120-5633200500020000300019&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">20. Smith RR, Hutchins    GM. Ischemic heart disease secondary to amyloidosis of intramyocardial arteries.    Am J Cardiol 1979; 44: 413.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000145&pid=S0120-5633200500020000300020&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">21. Hongo, M, Yamamoto    H, Kohda T, et al. Comparison of electrocardiographic findings in patients with    AL (primary) amyloidosis and in familial amyloid polyneuropathy and anginal    pain and their relation to histopathologic findings. Am J Cardiol 2000; 85:    849.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000146&pid=S0120-5633200500020000300021&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">22. Sedlis SP, Saffitz    JE, Schwob VS, Jaffe AS. Cardiac amyloidosis simulating hypertrophic cardiomyopathy.    Am J Cardiol 1984; 53: 969.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000147&pid=S0120-5633200500020000300022&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">23. Brodarick S,    Paine R, Higa E, Carmichael KA. Pericardial tamponade, a new complication of    amyloid heart disease. Am J Med 1982; 73: 133.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000148&pid=S0120-5633200500020000300023&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">24. Daubert JP,    Gaede J, Cohen HJ. A fatal case of constrictive pericarditis due to marked,    selective pericardial accumulation of amyloid. Am J Med 1993; 94: 335.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000149&pid=S0120-5633200500020000300024&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">25. Rahman JE, Helou    EF, Gelzer-Bell R, et al. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis.    J Am Coll Cardiol 2004; 43: 410.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000150&pid=S0120-5633200500020000300025&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">26. Klein AL, Hatle    LK, Burstow DJ, et al. Comprehensive Doppler assessment of right ventricular    diastolic function in cardiac amyloidosis. J Am Coll Cardiol 1990; 15: 99.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000151&pid=S0120-5633200500020000300026&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">27. Siqueira-Filho    AG, Cunha CLP, Tajik AJ, et al. M-mode and two-dimensional echocardiographic    features in cardiac amyloidosis. Circulation 1981; 63: 188 (abstract).</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000152&pid=S0120-5633200500020000300027&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">28. Patel AR, Dubrey    SW, Mendes LA, et al. Right ventricular dilatation in primary amyloidosis: an    independent predictor of survival. Am J Cardiol 1997; 80: 486.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000153&pid=S0120-5633200500020000300028&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">29. Falk RH, Plenn    JF, Deering T, et al. Sensitivity and specificity of echocardiographic features    of cardiac amyloidosis. Am J Cardiol 1987; 59: 418 (abstract).</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000154&pid=S0120-5633200500020000300029&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">30. Simons M, Isner    JM. Assessment of relative sensitivities of non-invasive tests for cardiac amyloidosis    in documented cardiac amyloidosis. Am J Cardiol 1992; 69: 425 (abstract).</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000155&pid=S0120-5633200500020000300030&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">31. Carroll JD,    Gaasch WH, McAdam KPWJ. Amyloid cardiomyopathy: characterization by a distinctive    voltage/mass relation. Am J Cardiol 1982; 49: 9.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000156&pid=S0120-5633200500020000300031&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">32. Pellikka PA,    Holmes DR Jr., Edwards WD, et al. Endomyocardial biopsy in 30 patients with    primary amyloidosis and suspected cardiac involvement. Arch Intern Med 1988;    148:662 (abstract).</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000157&pid=S0120-5633200500020000300032&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">33. Arbustini E,    Merlini G, Gavazzi A, et al. Cardiac immunocyte-derived amyloidosis: an endomyocardial    biopsy study in 11 patients. Am Heart J 1995; 130: 528.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000158&pid=S0120-5633200500020000300033&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">34. Kyle RA, Gertz    MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases.    Semin Hematol 1995; 32: 45.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000159&pid=S0120-5633200500020000300034&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">35. Dubrey SW, Cha    K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL)    amyloidosis with heart involvement. QJM 1998; 91: 141.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000160&pid=S0120-5633200500020000300035&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">36. Kyle RA, Gertz    MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine    alone, melphalan and prednisone, and melphalan, prednisone, and colchicine.    N Engl J Med 1997; 336: 1202.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000161&pid=S0120-5633200500020000300036&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">37. Grogan M, Gertz    MA, Kyle RA, Tajik AJ. Five or more years of survival in patients with primary    systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 2000;    85: 664. </font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000162&pid=S0120-5633200500020000300037&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">38. Dubrey S, Mendes    L, Skinner M, Falk RH. Resolution of heart failure in patients with AL amyloidosis.    Ann Intern Med 1996; 125: 481.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000163&pid=S0120-5633200500020000300038&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">39. Pelosi F, Capehart    J, Roberts WC. Effectiveness of cardiac transplantation for primary (AL) cardiac    amyloidosis. Am J Cardiol 1997; 79: 532. </font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000164&pid=S0120-5633200500020000300039&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">40. Dubrey SW, Burke    MM, Khaghani A, et al. Long term results of heart transplantation in patients    with amyloid heart disease. Heart 2001; 85: 202.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000165&pid=S0120-5633200500020000300040&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY"><font face="Times New Roman, Times, serif">41. Stangou AJ,    Hawkins PN, Heaton ND, et al. Progressive cardiac amyloidosis following liver    transplantation for familial amyloid polyneuropathy. Transplantation 1998; 66:    229.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000166&pid=S0120-5633200500020000300041&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gertz]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Kyle]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Primary systemic amyloidosis: A diagnostic primer]]></article-title>
<source><![CDATA[Mayo Clin Proc]]></source>
<year>1989</year>
<volume>64</volume>
<page-range>1505</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kyle]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Amyloidosis]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1995</year>
<volume>91</volume>
<page-range>1269</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dubrey]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Skinner]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[LaValley]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly 5 different clinical outcomes]]></article-title>
<source><![CDATA[Heart]]></source>
<year>1997</year>
<volume>78</volume>
<page-range>74</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gertz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kyle]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Thibodeau]]></surname>
<given-names><![CDATA[SN]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Familial amyloidosis: A study of 52 North American-born patients examined during a 30 year period]]></article-title>
<source><![CDATA[Mayo Clin Proc]]></source>
<year>1992</year>
<volume>67</volume>
<page-range>428</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jacobson]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Pastore]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Yaghoubian]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Variant sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1997</year>
<volume>336</volume>
<page-range>466</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cornwell]]></surname>
<given-names><![CDATA[GG]]></given-names>
</name>
<name>
<surname><![CDATA[Murdoch]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Kyle]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Frequency and distribution of senile cardiovascular amyloid]]></article-title>
<source><![CDATA[Am J Med]]></source>
<year>1983</year>
<volume>75</volume>
<page-range>618</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olson]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gertz]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Edwards]]></surname>
<given-names><![CDATA[WD]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Senile cardiac amyloidosis with myocardial dysfunction. Diagnosis by endomyocardial biopsy and immunohistochemistry]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1987</year>
<volume>317</volume>
<page-range>738</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[WC]]></given-names>
</name>
<name>
<surname><![CDATA[Waller]]></surname>
<given-names><![CDATA[BF]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cardiac amyloidosis causing cardiac dysfunction: analysis of 54 necropsy patients]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1983</year>
<volume>52</volume>
<page-range>137</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kyle]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Clinical significance of histological patterns of cardiac amyloidosis]]></article-title>
<source><![CDATA[Mayo Clin Proc]]></source>
<year>1984</year>
<volume>59</volume>
<page-range>547</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Swanton]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Brooksby]]></surname>
<given-names><![CDATA[IAB]]></given-names>
</name>
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Systolic and diastolic ventricular function in cardiac amyloidosis]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1977</year>
<volume>39</volume>
<page-range>658</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liao]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Jain]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Teller]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2001</year>
<volume>104</volume>
<page-range>1594</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chew]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ziady]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Raphael]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Oakley]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The functional defect in amyloid heart disease. The «stiff heart» syndrome]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1975</year>
<volume>36</volume>
<page-range>43</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reisinger]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Dubrey]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Lavalley]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement.]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>1997</year>
<volume>30</volume>
<page-range>1046</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dubrey]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Bilazarian]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[LaValley]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Signal averaged electrocardiography in patients with AL (primary) amyloidosis]]></article-title>
<source><![CDATA[Am Heart J]]></source>
<year>1997</year>
<volume>134</volume>
<page-range>994</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ridolfi]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Bulkley]]></surname>
<given-names><![CDATA[BH]]></given-names>
</name>
<name>
<surname><![CDATA[Hutchins]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The conduction system in cardiac amyloidosis]]></article-title>
<source><![CDATA[Am J Med]]></source>
<year>1977</year>
<volume>62</volume>
<page-range>677</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chamarthi]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Dubrey]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Cha]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Features and prognosis of exertional syncope in light-chain associated AL cardiac amyloidosis]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1997</year>
<volume>80</volume>
<page-range>1242</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mathew]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Olson]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gertz]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Symptomatic conduction system disease in cardiac amyloidosis]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1997</year>
<volume>80</volume>
<page-range>1491</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Al Suwaidi]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Velianou]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Gertz]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Systemic amyloidosis presenting as angina pectoris]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>1999</year>
<volume>131</volume>
<page-range>838</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mueller]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
<name>
<surname><![CDATA[Edwards]]></surname>
<given-names><![CDATA[WD]]></given-names>
</name>
<name>
<surname><![CDATA[Gertz]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis]]></article-title>
<source><![CDATA[Am J Med]]></source>
<year>2000</year>
<volume>109</volume>
<page-range>181</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
<name>
<surname><![CDATA[Hutchins]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Ischemic heart disease secondary to amyloidosis of intramyocardial arteries]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year></year>
<volume>44</volume>
<page-range>1979</page-range><page-range>413</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hongo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yamamoto]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kohda]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Comparison of electrocardiographic findings in patients with AL (primary) amyloidosis and in familial amyloid polyneuropathy and anginal pain and their relation to histopathologic findings]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2000</year>
<volume>85</volume>
<page-range>849</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sedlis]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Saffitz]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Schwob]]></surname>
<given-names><![CDATA[VS]]></given-names>
</name>
<name>
<surname><![CDATA[Jaffe]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cardiac amyloidosis simulating hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1984</year>
<volume>53</volume>
<page-range>969</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brodarick]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Paine]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Higa]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Carmichael]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Pericardial tamponade, a new complication of amyloid heart disease]]></article-title>
<source><![CDATA[Am J Med]]></source>
<year>1982</year>
<volume>73</volume>
<page-range>133</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Daubert]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Gaede]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A fatal case of constrictive pericarditis due to marked, selective pericardial accumulation of amyloid]]></article-title>
<source><![CDATA[Am J Med]]></source>
<year>1993</year>
<volume>94</volume>
<page-range>335</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rahman]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Helou]]></surname>
<given-names><![CDATA[EF]]></given-names>
</name>
<name>
<surname><![CDATA[Gelzer-Bell]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Noninvasive diagnosis of biopsy-proven cardiac amyloidosis]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2004</year>
<volume>43</volume>
<page-range>410</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Klein]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Hatle]]></surname>
<given-names><![CDATA[LK]]></given-names>
</name>
<name>
<surname><![CDATA[Burstow]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Comprehensive Doppler assessment of right ventricular diastolic function in cardiac amyloidosis]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>1990</year>
<volume>15</volume>
<page-range>99</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Siqueira-Filho]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Cunha]]></surname>
<given-names><![CDATA[CLP]]></given-names>
</name>
<name>
<surname><![CDATA[Tajik]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[M-mode and two-dimensional echocardiographic features in cardiac amyloidosis]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1981</year>
<volume>63</volume>
<page-range>188</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Dubrey]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Mendes]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Right ventricular dilatation in primary amyloidosis: an independent predictor of survival]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1997</year>
<volume>80</volume>
<page-range>486</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Falk]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Plenn]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Deering]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Sensitivity and specificity of echocardiographic features of cardiac amyloidosis]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1987</year>
<volume>59</volume>
<page-range>418</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simons]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Isner]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Assessment of relative sensitivities of non-invasive tests for cardiac amyloidosis in documented cardiac amyloidosis]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1992</year>
<volume>69</volume>
<page-range>425</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carroll]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Gaasch]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
<name>
<surname><![CDATA[McAdam]]></surname>
<given-names><![CDATA[KPWJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1982</year>
<volume>49</volume>
<page-range>9</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pellikka]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Holmes]]></surname>
<given-names><![CDATA[DR Jr]]></given-names>
</name>
<name>
<surname><![CDATA[Edwards]]></surname>
<given-names><![CDATA[WD]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Endomyocardial biopsy in 30 patients with primary amyloidosis and suspected cardiac involvement]]></article-title>
<source><![CDATA[Arch Intern Med]]></source>
<year>1988</year>
<volume>148</volume>
<page-range>662</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arbustini]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Merlini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gavazzi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cardiac immunocyte-derived amyloidosis: an endomyocardial biopsy study in 11 patients]]></article-title>
<source><![CDATA[Am Heart J]]></source>
<year>1995</year>
<volume>130</volume>
<page-range>528</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kyle]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Gertz]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Primary systemic amyloidosis: clinical and laboratory features in 474 cases]]></article-title>
<source><![CDATA[Semin Hematol]]></source>
<year>1995</year>
<volume>32</volume>
<page-range>45</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dubrey]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Cha]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement]]></article-title>
<source><![CDATA[QJM]]></source>
<year>1998</year>
<volume>91</volume>
<page-range>141</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kyle]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Gertz]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Greipp]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1997</year>
<volume>336</volume>
<page-range>1202</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grogan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gertz]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Kyle]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Tajik]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Five or more years of survival in patients with primary systemic amyloidosis and biopsy-proven cardiac involvement]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2000</year>
<volume>85</volume>
<page-range>664</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dubrey]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mendes]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Skinner]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Falk]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Resolution of heart failure in patients with AL amyloidosis]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>1996</year>
<volume>125</volume>
<page-range>481</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pelosi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Capehart]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[WC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effectiveness of cardiac transplantation for primary (AL) cardiac amyloidosis]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1997</year>
<volume>79</volume>
<page-range>532</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dubrey]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Burke]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Khaghani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Long term results of heart transplantation in patients with amyloid heart disease]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2001</year>
<volume>85</volume>
<page-range>202</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stangou]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hawkins]]></surname>
<given-names><![CDATA[PN]]></given-names>
</name>
<name>
<surname><![CDATA[Heaton]]></surname>
<given-names><![CDATA[ND]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy]]></article-title>
<source><![CDATA[Transplantation]]></source>
<year>1998</year>
<volume>66</volume>
<page-range>229</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
